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Abstract
Background: Population screening with mammography has resulted in increased detection of ductal carcinoma in
situ (DCIS). The aim of this population-based cohort study was to assess whether the method of detection should
be considered when determining prognosis and treatment in women with DCIS.
Methods: This study includes 7042 women aged 49–75 years, who were surgically treated for primary DCIS between
1989 and 2004 in the Netherlands. We calculated cumulative incidences of ipsilateral and contralateral invasive breast
cancer and all-cause mortality among women with screen-detected, interval, or non-screening-related DCIS, and assessed
the association between method of detection and these outcomes, using multivariable Cox regression analyses.
Results: Compared with non-screening-related DCIS, women with screen-detected DCIS had a lower risk of developing
ipsilateral invasive breast cancer (hazard ratio (HR) = 0.75, 95% CI = 0.59–0.96), but a similar risk of contralateral invasive
breast cancer (HR = 0.86, 95% CI = 0.67–1.10). The absolute difference in risk of ipsilateral invasive breast cancer was 1% at
15 years. Screen detection was associated with lower all-cause mortality (HR = 0.85, 95% CI = 0.73–0.98); when we
additionally accounted for the occurrence of invasive breast cancer the magnitude of this effect remained similar (HR = 0.
86, 95% CI = 0.75–1.00).
Conclusions: Screen detection was associated with lower risk of ipsilateral invasive breast cancer and all-cause mortality.
However, the absolute difference in risk of ipsilateral invasive breast cancer was very low and the lower all-cause mortality
associated with screen-detected and interval DCIS might be explained by a healthy-user effect. Therefore, our findings do
not justify different treatment strategies for women with screen-detected, interval, or non-screening-related DCIS.
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Background
Population-based breast cancer screening has been in-
troduced on the basis of evidence that mammographic
screening could reduce mortality in breast cancer. Yet,
there is an ongoing debate about one of the major con-
cerns of screening, overdiagnosis, which is the detection
of an abnormality that would never have caused symp-
toms or death during one’s lifetime if screening had been
omitted [1–7]. Unfortunately, we are not able to distin-
guish between women who are overdiagnosed and
women who do need treatment. Therefore, we tend to
treat them all. This implies that overdiagnosis results in
overtreatment [8].
Population screening with mammography has resulted in
increased detection of ductal carcinoma in situ (DCIS), a
non-obligate precursor lesion for invasive breast cancer.
Several studies have indicated an association between
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mammographic screening and overdiagnosis and overtreat-
ment of DCIS [9–12]. On the other hand, a recent eco-
logical study reported that a higher rate of screen-detected
DCIS is associated with a lower rate of invasive interval
cancers, suggesting that detection and treatment of DCIS is
worthwhile [13].
Method of detection has been shown to be an independ-
ent prognostic factor beyond stage migration in patients
with invasive breast carcinoma [14, 15]. Women with inva-
sive breast cancer detected at population-based screening
have been shown to have better overall and breast cancer-
specific survival than those who have not participated in
the screening program, with an absolute reduction in breast
cancer-specific mortality of 7% at 10 years [14].
Previous studies suggest that the method of detection
may also carry prognostic information in women treated
for DCIS [16–19], but it is still unclear whether women
with screen-detected DCIS have a clinically relevant bet-
ter prognosis than women with non-screening-related
DCIS and whether the method for detection should be
used in the treatment decision-making process, such as
the addition or omission of radiotherapy and anti-
estrogen treatment. To this end, we studied risk of
subsequent ipsilateral and contralateral invasive breast
cancer and all-cause mortality among a large
population-based cohort of women with screen-
detected, interval, and non-screening-related DCIS.
Methods
Patient selection
All women who were diagnosed with DCIS in the
Netherlands from 1989 through 2004, and who had no
previous malignancies except for non-melanoma skin can-
cer, were selected from a cohort based on linked data from
the Netherlands Cancer Registry (NCR) and the nation-
wide network and registry of histology and cytopathology
in the Netherlands (PALGA) [20]. To be eligible for the
current study we required: (1) a diagnosis of pure DCIS;
(2) age 49–75 years at DCIS diagnosis; (3) DCIS treatment
consisting of breast-conserving surgery plus radiotherapy,
breast-conserving surgery alone, or mastectomy; and (4)
no invasive breast cancer or second breast carcinoma in
situ within 4 months after initial DCIS diagnosis. Women
who were diagnosed at autopsy (n = 1), women in whom
the type of surgery could not be determined (n = 59), and
women who received chemotherapy or hormonal therapy
for DCIS (n = 47) were excluded.
Breast cancer screening program
The Dutch breast cancer screening program started in
1989 [21]. From 1989 to 1997 women aged 50–69 years
were the target population. Full coverage of these
women was achieved in 1997 [22, 23]. In 1998 the pro-
gram was extended to women aged 70–75 years. In the
Dutch screening program women receive an invitation
for screening mammography once every 2 years starting
in the year the women turn 50 or 51 years. Invitations
for the next round are issued within 24 + 2 months of
the prior screening. For women who move to another
local authority area the next screening could be delayed
up to 6 months. Screening mammograms are performed
in independent and mostly mobile screening units, and
the images are interpreted double-blinded by trained ra-
diologists. Information about screening mammography
is recorded by the five regional screening facilities and
collected in the database of the Dutch breast cancer
screening organization.
Method of detection
To obtain information about the method of detection
we linked our dataset with the database of the Dutch
breast cancer screening organization. We classified three
categories of DCIS on the basis of method of detection:
(1) screen-detected DCIS, defined as DCIS that was de-
tected <12 months after a first or subsequent positive
screening examination in the Dutch breast cancer
screening program; (2) interval DCIS, defined as DCIS
diagnosed <30 months after a negative screening exam-
ination, or diagnosed 12–30 months after a positive
screening examination; and (3) DCIS detected outside
the breast cancer screening program (non-screening-re-
lated), defined as DCIS diagnosed ≥30 months after the
screening examination, diagnosed prior to the first
screening examination, or diagnosed in women who
never participated in the program.
Women who had ever participated in the screening pro-
gram, but for whom method of DCIS detection was un-
known, were excluded from the analyses (n = 525). To
examine possible confounding by excluding this group of
women, we compared the risk of subsequent ipsilateral
and contralateral invasive breast cancer and all-cause mor-
tality between this group and the group of women with a
known method of detection: no significant differences
were found. Our study cohort included 7042 women in
whom the method of detection was known.
Because of the gradual implementation of the screening
program in the Netherlands, we defined two periods of
DCIS diagnosis, 1989–1998 and 1999–2004. In the first
period the women with non-screening-related DCIS were
more likely not to be invited for breast cancer screening,
while in the later period, the group of women with non-
screening-related DCIS could have comprised more women
who chose not to participate in breast cancer screening.
Treatment and grade
Information about surgical DCIS treatment was obtained
from the NCR database and further completed based on
PALGA data. Further, the NCR provided information on
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whether radiotherapy was administered. Initial DCIS
treatment was defined as the treatment strategy for the
primary DCIS lesion within 3 months of diagnosis.
Three categories were classified: breast-conserving sur-
gery plus radiotherapy, breast-conserving surgery alone,
and mastectomy. Additionally, using PALGA data we
assessed whether women initially treated by breast-
conserving surgery had undergone ipsilateral mastec-
tomy during follow up (due to any cause other than
ipsilateral invasive breast cancer). Information on grade
was derived from the NCR and was available for 56.4%
of the analytical cohort. The grading system used in the
Netherlands is based on the classification presented by
Holland et al. [24].
Outcome data and statistical analyses
Follow up of ipsilateral and contralateral invasive breast
cancer and vital status was obtained from the NCR and
PALGA databases and was complete up to 1 January
2011. The period of time at risk started at the date of
DCIS diagnosis, and stopped at the date of the event of
interest, emigration, or 31 December 2010, whichever
came first.
Up to 15-year cumulative incidences of ipsilateral and
contralateral invasive breast cancer were calculated ac-
cording to method of detection, using death as a compet-
ing risk. All-cause mortality was calculated according to
method of detection and age group at DCIS diagnosis
using the Kaplan-Meier method. P values were based ei-
ther on competing risk regression [25] or Cox propor-
tional hazards regression, with time since DCIS diagnosis
as the time scale and adjusted for age (continuous).
We used multivariable-adjusted Cox proportional haz-
ards analyses to estimate relative differences in risk of
ipsilateral and contralateral invasive breast cancer and
all-cause mortality among women with screen-detected,
interval, and non-screening-related DCIS. In these ana-
lyses we used age as the primary time scale, and time
since DCIS diagnosis (0–5, 5–10, and ≥10 years) as sec-
ondary time scale. We adjusted for DCIS treatment
(time-varying), DCIS grade and period of diagnosis.
We performed a supplementary analysis restricted to
women participating in the implemented Dutch screen-
ing program, in which we compared risk of ipsilateral
and contralateral invasive breast cancer and mortality
among women with screen-detected vs. interval DCIS
between 1999 and 2004.
Data on cause of death were not available in this study.
In an attempt to correct for death due to invasive breast
cancer we additionally included the occurrence of ipsi-
lateral and contralateral invasive breast cancer as time-
varying covariables in the model, with all-cause mortality
as outcome.
The proportional hazard assumption was verified using
graphical and residual-based methods. Furthermore, we
assessed whether the effect of method of detection was
modified by period of diagnosis by introducing an appro-
priate interaction term in the model.
A P value <0.05 was considered statistically significant.
All analyses were performed with STATA/SE 13.1 (Stata-
Corp LP, College Station, TX, USA). The study was ap-
proved by the review boards of the NCR, PALGA, and
the Dutch breast cancer screening organization.
Results
Study population and method of detection
The study cohort comprised 4814 women with screen-
detected DCIS, 651 with interval DCIS, and 1577 with
non-screening-related DCIS. Among the women with
screen-detected DCIS, 1622 (34%) were detected in the first
screening round (i.e. prevalent DCIS), and 3192 (66%) in a
subsequent screening round (i.e. incident DCIS).
Most screen-detected DCIS was diagnosed within
2 months after the screening mammogram was per-
formed (90th percentile) (Additional file 1). The propor-
tion of screen-detected DCIS increased over time (P <
0.001), whereas the absolute number of non-screening-
related DCIS remained stable (Fig. 1). The distribution
of grade was dependent on screening status (P < 0.001)
(Table 1). Of the women with screen-detected DCIS,
59% were treated by breast-conserving surgery, com-
pared to 51% of interval DCIS, and 46% of non-
screening-related DCIS (Table 1). The proportion of
women undergoing mastectomy decreased over time in
all detection groups (P < 0.001).
Ipsilateral and contralateral invasive breast cancer
With a median follow up of 10.5 years (interquartile
range = 7.7–14.0), 363 and 378 of 7042 women were di-
agnosed with ipsilateral and contralateral invasive breast
cancer, respectively. Women with screen-detected DCIS
had lower risk of ipsilateral invasive breast cancer than
women with non-screening-related DCIS (adjusted haz-
ard ratio (HR) = 0.75, 95% confidence interval (CI) =
0.59–0.96) (Table 2, Additional file 2). The absolute dif-
ference in risk of ipsilateral invasive breast cancer at
15 years of follow up, between screen-detected and non-
screening-related DCIS was 1% (cumulative incidence =
6% vs. 7%, respectively) (Fig. 2). No statistically signifi-
cant difference was observed between interval and non-
screening-related DCIS (HR = 1.02, 95% CI = 0.68–1.51).
Risk of contralateral invasive breast cancer was not as-
sociated with method of detection (screen-detected vs.
non-screening-related DCIS: HR = 0.86, 95% CI = 0.67–
1.10; interval versus non-screening-related DCIS: HR =
0.83, 95% CI = 0.54–1.26) (Table 2, Additional file 2).
During the 15-year follow-up period, the cumulative
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incidence of contralateral invasive breast cancer was
similar to the cumulative incidence of ipsilateral invasive
breast cancer (Fig. 2). The association between method
of detection and risk of ipsilateral invasive breast cancer
did not differ by period of diagnosis (Pinteraction = 0.540),
nor did it for contralateral invasive breast cancer risk
(Pinteraction = 0.282).
All-cause mortality
During follow up, 1060 of 7042 women died. In a
multivariable-adjusted model, adjusted for treatment,
grade and period of diagnosis, having a screen-detected
or interval DCIS was associated with lower all-cause
mortality compared to non-screening-related DCIS (for
screen-detected DCIS, HR = 0.85, 95% CI = 0.73–0.98;
for interval DCIS, HR = 0.73, 95% CI = 0.56–0.96)
(Table 2, Additional file 3). Additional adjustment for
the occurrence of invasive breast cancer did not affect
these risk estimates, while the confidence interval chan-
ged only slightly (HR = 0.86, 95% CI = 0.75–1.00 for
screen-detected DCIS; HR = 0.73, 95% CI = 0.56–0.96 for
interval DCIS). The association between method of de-
tection and all-cause mortality did not change with
period of diagnosis (Pinteraction = 0.531). Figure 3 shows
the Kaplan-Meier curves for all-cause mortality by
method of detection; there was no difference between
screen-detected and interval DCIS. Differences in all
cause-mortality between women attending screening
(with screen-detected or interval DCIS) and women with
non-screening-related DCIS were only detected in
women aged 60–69 years (P < 0.001) (Additional file 4).
In the supplementary analysis, we found that women
with interval DCIS tended to have higher risk of
ipsilateral invasive breast cancer than women with
screen-detected DCIS (HR 1.64; 95% CI 0.99–2.72),
whereas the risk of contralateral invasive breast cancer
was similar (HR 1.01; 95% CI 0.61–1.67) (Additional file
5). In addition, the risk of dying was similar in women
with screen-detected DCIS and women with interval
DCIS (HR 1.00; 95% CI 0.70–1.41) (Additional file 6).
Discussion
This large nationwide cohort provides a unique oppor-
tunity to assess whether women with screen-detected
DCIS have a clinically relevant better prognosis than
women with non-screening-related DCIS and whether
the method of detection should be used in the treatment
decision-making process. We found that women with
screen-detected DCIS had lower risk of subsequent ipsi-
lateral invasive breast cancer, irrespective of age and
treatment, compared to women with DCIS that was not
detected within the national screening program. How-
ever, the absolute difference in risk of ipsilateral invasive
breast cancer was very small; 6% of patients with screen-
detected DCIS and 7% of patients with non-screening-
related DCIS had developed ipsilateral invasive breast
cancer at 15 years.
Further, we observed that women with screen-detected
and interval DCIS had lower all-cause mortality compared
to women with non-screening-related DCIS. Time-
dependent adjustment for invasive breast cancer did not
change the effect estimates, suggesting that the difference is
caused by death due to causes other than invasive breast
cancer. Importantly, this is circumstantial evidence and we
cannot rule out that the difference may be partly explained
by breast cancer mortality. However, breast cancer-specific
Fig. 1 Method of detection by year of diagnosis of ductal carcinoma in situ (DCIS)
Elshof et al. Breast Cancer Research  (2017) 19:26 Page 4 of 10
Table 1 Characteristics of the study population by method of detection
Method of detection Non-screening-related Screen-detected Interval
DCIS diagnosis
Within 12 months after positive first screening, n (%) NA 1622 (33.7) NA
Within 12 months after positive subsequent screening, n (%) NA 3192 (66.3) NA
Within 30 months of negative screening, n (%) NA NA 577 (88.6)
12 to 30 months after positive screening, n (%) NA NA 74 (11.4)
≥30 months after screening participation, n (%) 159 (10.1) NA NA
Prior to first screening participation, n (%) 115 (7.3) NA NA
In women who never participated in the screening program, n (%) 1303 (82.6) NA NA
Mammography typea
Conventional (film) 159 4804 651
Digital 0 10 0
Age at DCIS diagnosis, years
Median (interquartile range) 58.1 (51.9–66.8) 58.7 (53.5–64.3) 59.8 (55.0–65.7)
49–59, n (%) 868 (55.0) 2676 (55.6) 327 (50.2)
60–69, n (%) 450 (28.5) 1789 (37.2) 262 (40.3)
70–75, n (%) 259 (16.4) 349 (7.3) 62 (9.5)
Period of DCIS diagnosis
1989–1998 (implementation phase), n (%) 1044 (66.2) 2001 (41.6) 215 (33.0)
1999–2004 (full nationwide coverage), n (%) 533 (33.8) 2813 (58.4) 436 (67.0)
DCIS grade
1 126 (8.0) 440 (9.1) 90 (13.8)
2 188 (11.9) 926 (19.2) 127 (19.5)
3 288 (18.3) 1577 (32.8) 208 (32.0)
Unknownb 975 (61.8) 1871 (38.9) 226 (34.7)
DCIS treatment within 3 months of diagnosis
Breast-conserving surgery with radiotherapy, n (%) 276 (17.5) 1587 (33.0) 188 (28.9)
Breast-conserving surgery without radiotherapy, n (%) 443 (28.1) 1256 (26.1) 144 (22.1)
Mastectomy, n (%) 858 (54.4) 1971 (40.9) 319 (49.0)
Follow-up interval, years
Median (interquartile range) 12.2 (8.1–16.4) 10.3 (7.7–13.5) 9.9 (7.3–12.5)
0–4c, n (%) 115 (7.3) 179 (3.7) 29 (4.5)
5–9, n (%) 461 (29.2) 2117 (44.0) 305 (46.9)
≥10, n (%) 1001 (63.5) 2518 (52.3) 317 (48.7)
Subsequent invasive breast cancerd
No, n (%) 1385 (87.8) 4357 (90.5) 592 (90.9)
Ipsilateral only, n (%) 87 (5.5) 213 (4.4) 29 (4.5)
Contralateral only, n (%) 94 (6.0) 225 (4.7) 25 (3.8)
Ipsilateral + contralateral, n (%) 11 (0.7) 18 (0.4) 5 (0.8)
Vital status at last follow up
Alive, n (%) 1153 (73.1) 4191 (87.1) 575 (88.3)
Dead, n (%) 398 (25.2) 594 (12.3) 68 (10.5)
Emigrated, n (%) 26 (1.7) 29 (0.6) 8 (1.2)
Total 1577 4814 651
aLast screening mammogram before diagnosis of ductal carcinoma in situ (DCIS). b1989–1998: 75% unknown vs. 1999–2004: 16% unknown. cEight patients with
follow-up time = 0. dOne patient with unknown laterality of subsequent invasive breast cancer. NA not applicable
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mortality in women with DCIS is very low [26]. Therefore,
if the difference in all-cause mortality is partly caused by
breast cancer mortality, the absolute difference in breast
cancer mortality between screen-detected, interval, and
non-screening-related DCIS will likely be very small and
clinically not significant.
Another possible explanation for lower all-cause mortal-
ity in women who participate in mammographic screening
is the healthy-user effect [27]. The healthy-user effect oc-
curs when patients who choose to receive one preventive
service also choose to receive other preventive services.
These patients also may have less comorbidity and better
functional status, increasing the likelihood of other
healthy behaviors. This is supported by a Dutch study, in
which the attendance rate for breast cancer screening was
lower among women with a low socioeconomic status,
and comorbidity was inversely associated with socioeco-
nomic status [28]. A healthy-user effect among women
who attend mammographic screening is also supported by
other studies [29–32]. Based on the available evidence, the
healthy-user effect might explain the better overall sur-
vival in women with screen-detected DCIS.
In earlier studies the association between method of de-
tection and the development of subsequent invasive breast
cancer was tested in patients with DCIS, but a recent
meta-analysis showed that the classification of detection
method varied and had not been uniformly defined [16].
As a consequence, interpreting the association between
method of detection and outcome of treatment of DCIS is
more difficult. A few studies have evaluated whether
women with DCIS detected through a population-based
screening program have better prognosis than women
with non-screening-related DCIS [18, 19], and therefore
can be compared to our findings. Cheung et al. [19] (n =
3930 subjects, length of follow up not reported) found
that the difference in risk of ipsilateral invasive breast can-
cer between screen-detected and non-screening-related
DCIS was somewhat larger than in our study (annual ab-
solute risk 0.43% vs. 0.65%; HR = 0.32, P value <0.0001),
possibly because of variation in selection criteria. Our
study only included women who were eligible for partici-
pation in the population-based screening program based
on age, whereas Cheung et al. analyzed all women, and
thus also included younger women (<50 years) who have a
higher risk of invasive breast cancer compared to older
women [33]. Falk et al. [18] (n = 3163 subjects, median fol-
low up 5.2 years) reported a lower risk of ipsilateral inva-
sive breast cancer in screen-detected DCIS, which was
comparable to our results (HR = 0.7, 95% CI = 0.4–1.1),
but did not report absolute risk estimates for groups ac-
cording to different methods of detection.
The meta-analysis by Zhang et al. included six studies;
in five of these studies mammographically detected
DCIS was compared with symptomatic or palpable DCIS
[16]. Unfortunately, we had no information on whether
the DCIS was detected by mammography or by clinical
symptoms. In addition, the non-screening-related group
might also include women who attended opportunistic
screening or who were at higher risk of breast cancer
and therefore attended a different screening program.
However, Zhang et al. reported a higher risk of ipsilateral
invasive breast cancer in symptomatic DCIS, which was
comparable to the higher risk in non-screening-related
DCIS in our study (HR = 1.38, 95% CI = 1.12–1.63 and
HR = 1.33, 95% CI = 1.04–1.70, respectively).
It has been postulated that the difference in risk of ipsi-
lateral invasive breast cancer between screen-detected and
non-screening-related DCIS might be due to differences in
the underlying biology of DCIS [34–36]. Symptomatic
presentation has been shown to be associated with larger
Table 2 Multivariable-adjusted Cox regression analyses for different events in women aged 49–75 years at DCIS diagnosis
Method of detection Total number of events Person-time, years HR (95% CI) P value
Ipsilateral invasive breast cancer
Non-screening-related 98 18,710 ref
Screen-detected 231 50,422 0.75 (0.59–0.96) 0.024
Interval 34 6359 1.02 (0.68–1.51) 0.941
Contralateral invasive breast cancer
Non-screening-related 105 18,825 ref
Screen-detected 243 50,467 0.86 (0.67–1.10) 0.224
Interval 30 6387 0.83 (0.54–1.26) 0.382
All-cause mortality
Non-screening-related 398 19,361 ref
Screen-detected 594 51,740 0.85 (0.73–0.98) 0.028
Interval 68 6570 0.73 (0.56 − 0.96) 0.025
Analysis was performed with age as the primary time scale and time since DCIS diagnosis (0–5, 5–10, and ≥10 years) as the secondary time scale. We adjusted for
period of ductal carcinoma in situ (DCIS) diagnosis, DCIS grade and DCIS treatment (time-varying). HR hazard ratio, CI confidence interval
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lesion size and higher risk of estrogen receptor negativity
[34, 35]. Triple-negative, human epidermal growth factor
receptor 2 (HER2), and basal-like phenotypes were found
to be more common in symptomatic DCIS, while the
luminal A phenotype was more often observed in screen-
detected DCIS [35]. Although there was a larger propor-
tion of low-grade DCIS in the screen-detected group in
one study, in others there was no difference in distribution
by grade [34–36]. Also in a recent Dutch study, the distri-
bution by grade was not dependent on mass screening sta-
tus (screened population in the breast cancer screening
program vs. population not subjected to/participating in
mass screening) [37]. In our study the distribution by grade
was dependent on screening status, but the difference in
risk of ipsilateral invasive breast cancer between screen-
detected and non-screening-related DCIS was independent
of grade. Unfortunately, there was no information available
to explore other differences in the biology of DCIS.
Breast density might be another explanation for the ob-
served lower risk of ipsilateral invasive breast cancer
among women with screen-detected DCIS. As high breast
density is associated with decreased mammographic ac-
curacy and increased risk of breast cancer [38, 39], it
might be hypothesized that women with screen-detected
DCIS have relatively low breast density and therefore con-
fer a lower risk of subsequent breast cancer as compared
with women with interval DCIS.
The association between method of detection and
mortality in women with DCIS has been studied less fre-
quently. Our results are in line with the study by Koh et
al. (n = 1202 subjects, median follow up 8.2 years), which
showed that women with screen-detected DCIS had bet-
ter overall survival than women with symptomatic DCIS
[35]. The high overall survival rates (100% and 97.8% at
10 years, respectively) presented by the authors can be
explained by the large proportion (45%) of women aged
<50 years at diagnosis in their study.
The prognostic value of the detection method seems to
be different in patients with DCIS compared to patients
with invasive breast cancer. As considerably better overall
survival and breast cancer-specific survival has been ob-
served in studies of women with screen-detected invasive
breast cancer compared with non-screening-related inva-
sive breast cancer, it has been suggested that method of
detection should be used when selecting patients for adju-
vant systemic therapy and that withholding chemotherapy
for patients with screen-detected invasive cancer could be
considered [14, 15, 40]. In contrast, our results do not
support treatment decision-making, such as omitting radi-
ation after breast-conserving surgery or using adjuvant
hormonal therapy [41], based on the method of detection.
A major strength of our study is that detailed informa-
tion from the Dutch breast cancer screening program was
available for this large population-based cohort with sub-
stantial follow up. On top of this, we had complete data
on treatment type and therefore were able to adjust for
this factor in the multivariable analyses. In addition, by
using age as the primary time scale in these multivariable
analyses we were able to correct for age in the most
optimal way.
A limitation is that the non-screening-related group rep-
resents a heterogeneous group, including both women
who were not invited in the screening program and
women who refused to participate. However, we found
that the association between method of detection and all
three outcomes was similar among women diagnosed
Fig. 2 Cumulative incidence of ipsilateral (a) and contralateral (b)
invasive breast cancer by method of detection, with death analyzed
as a competing risk. P values based on competing risk regression
with time since diagnosis of ductal carcinoma in situ as the primary
time scale, adjusted for age (continuous) [25]
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between 1989 and 1998 (most likely random selection)
and 1999 and 2004 (subject to selection bias).
Another important question is to what extent our re-
sults reflect the current situation in which screen-film
mammography has been replaced by full-field digital
mammography in most Western breast cancer screening
programs. Digital mammography seems to be associated
with a higher rate of detection of DCIS [42–44]. How-
ever, in a recent Dutch study to determine whether this
transition has resulted in changes in performance indica-
tors and characteristics of screen-detected and interval
cancers, there was no increased incidence of DCIS [45].
Moreover, opposing effects have been reported on the
distribution of grade. Both a higher proportion of low-
grade DCIS [46] and a higher proportion of high-grade
DCIS [42] at digital mammography have been described.
Further, others have found no differences in the distribu-
tion of grade after digital mammography compared with
screen-film mammography [43, 45]. These discrepancies
complicate the translation of our results to the current
digital era, but also suggest that the truth lies some-
where in between. Therefore, our results are likely very
relevant for patients diagnosed with DCIS today.
Conclusions
This study showed that having screen-detected DCIS was
associated with lower risk of ipsilateral invasive breast
cancer, but the absolute differences in risk of ipsilateral
invasive breast cancer were not clinically significant.
Women with screen-detected and interval DCIS had
lower all-cause mortality compared with women with
non-screening-related DCIS, which might be explained by
the healthy-user effect based on the available evidence.
Therefore, our findings indicate a limited prognostic role
of the method of detection of DCIS, and do not justify dif-
ferent treatment strategies for women with screen-
detected, interval, or non-screening-related DCIS.
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Additional file 1: Time (days) between a first or subsequent screening
examination by the Dutch breast cancer screening program and DCIS
diagnosis in women with screen-detected DCIS (DCIS diagnostic period
1989–2004) (DOCX 17 kb)
Additional file 2: Multivariable-adjusted Cox regression analysis of
ipsilateral and contralateral invasive breast cancer in women aged
49–75 years at DCIS diagnosis (DCIS diagnostic period 1989–2004).
Age was the primary time scale, time since DCIS diagnosis (0–5, 5–
10, and ≥10 years) the secondary time scale, and DCIS treatment a
time-varying covariable (DOCX 22 kb)
Additional file 3: Multivariable-adjusted Cox regression analysis of overall
mortality in women aged 49–75 years at DCIS diagnosis (DCIS diagnostic
period 1989–2004). Age was the primary time scale and time since DCIS
diagnosis (0–5, 5–10, and ≥10 years) the secondary time scale. Model 1 was
adjusted for period of DCIS diagnosis, DCIS grade, and DCIS treatment
(time-varying). Model 2 was adjusted for period of DCIS diagnosis, DCIS
grade, DCIS treatment (time-varying), and the occurrence of ipsilateral and
contralateral invasive breast cancer (time-varying) (DOCX 21 kb)
Fig. 3 Kaplan-Meier curves for all-cause mortality by method of detection. P values based on Cox proportional hazards regression with time since
diagnosis of ductal carcinoma in situ as the primary time scale, adjusted for age (continuous)
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Additional file 4: Kaplan-Meier curves for all-cause mortality by method
of detection for patients aged 49–59 years at DCIS diagnosis (a), patients
aged 60–69 years at DCIS diagnosis (b), and patients aged 70–75 years (c)
at DCIS diagnosis (DCIS diagnostic period 1989–2004). P values based on
Cox proportional hazards regression with time since DCIS diagnosis as
the primary time scale, adjusted for age (continuous). (DOCX 52 kb)
Additional file 5: Multivariable-adjusted Cox regression analysis of
ipsilateral and contralateral invasive breast cancer in women aged 49–75
years at DCIS diagnosis: comparison between screen-detected and interval
DCIS (DCIS diagnostic period 1999–2004 (screening implemented)). Age
was the primary time scale and time since DCIS diagnosis (0–5, 5–10, and
≥10 years) the secondary time-scale. (DOCX 21 kb)
Additional file 6: Multivariable-adjusted Cox regression analysis of
overall mortality in women aged 49–75 years at DCIS diagnosis:
comparison between screen-detected and interval DCIS (DCIS diagnostic
period 1999–2004 (screening implemented)). Age was the primary time
scale and time since DCIS diagnosis (0–5, 5–10, and ≥10 years) was the
secondary time scale. Model 1 was adjusted for period of DCIS diagnosis,
DCIS grade, and DCIS treatment (time-varying). Model 2 was adjusted for
period of DCIS diagnosis, DCIS grade, DCIS treatment (time-varying), and
the occurrence of ipsilateral and contralateral invasive breast cancer
(time-varying). (DOCX 20 kb)
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